New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
16:33 EDTFDO, HSH, ACHN, HITT, PPC, AAPL, MRK, CNSI, DG, TSN, GILD, IDIX, ADIOn The Fly: Closing Wrap
Stocks on Wall Street were slightly higher after a session that major averages spent mostly drifting just north of their starting points. The Dow and S&P 500 hit new highs once again despite the sluggish news flow, with the main news of the day being M&A stories that all hit either over the weekend or early this morning. ECONOMIC EVENTS: In the U.S., no significant economic data was reported. In China, data released over the weekend showed its trade surplus widened in May to $35.92B, as the nation's exports accelerated and its imports fell. COMPANY NEWS: Idenix Pharmaceuticals (IDIX) surged $16.56, or 229.05%, to $23.79 after pharmaceutical giant Merck (MRK) agreed to acquire the smaller drugmaker, which has valuable assets in the hepatitis C virus space, for $24.50 per share in cash. The deal, which values Idenix at about $3.85B, prompted analyst commentary that Achillion (ACHN), which is also developing HCV treatments, is an acquisition candidate and Achillion's shares finished up $1.37, or 47.57%, to $4.25. Shares of Gilead (GILD), which sells the drug, Sovaldi, that is widely seen as the current leader in the HCV space, fell $3.39, or 4.11%, to $79.00 following the news... Shares of a number of dollar store operators climbed after after well-known activist investor Carl Icahn disclosed that he had obtained a significant stake in one of the company in the space, Family Dollar (FDO), and subsequently told Fox Business that he may push for a merger between the company and peer Dollar General (DG)... Apple (AAPL) shares were in focus as its 7-for-1 stock split took effect. The newly split shares finished the day up $1.48, or 1.6%, at $93.70. MAJOR MOVERS: Among the notable gainers was Hittite Microwave (HITT), which surged $17.34, or 28.63%, to $77.90 after Analog Devices (ADI) agreed to acquire the company for $78 per share in cash. Shares of Analog Devices also gained $2.62, or 4.97%, to $55.31 following the news. Also higher was Hillshire Brands (HSH), which rose $3.14, or 5.33%, to $62.06 after Tyson Foods (TSN) increased its offer to acquire the company to $63 per share. Pilgrim's Pride (PPC), which was prompted to withdraw its own takeover proposal to Hillshire after Tyson raised its bid, fell $1.76, or 6.7%, to $24.51. Also lower were shares of Comverse (CNSI), which fell $2.13, or 8.53%, to $22.83 following the company's report of losses in its first quarter. INDEXES: The Dow was up 18.82, or 0.11%, to 16,943.10, the Nasdaq was up 12.31, or 0.28%, to 4,333.71, and the S&P 500 was up 1.83, or 0.09%, to 1,951.27.
News For IDIX;MRK;ACHN;GILD;AAPL;HSH;TSN;PPC;FDO;DG;HITT;ADI;CNSI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
January 13, 2015
12:15 EDTGILDExpress Scripts CEO says Gilead relationship 'important' going forward
Express Scripts (ESRX) CEO George Paz at the J.P. Morgan Healthcare Conference said his company's relationship with Gilead (GILD) is "important" going forward. Paz said his company's goal is not to exclude drugs. He continues to discuss Express Scripts's deal with AbbVie (ABBV) and the company's goal of saving clients money with regards to healthcare costs.
12:10 EDTGILDExpress Scripts CEO says 'never stopped talking to Gilead'
Subscribe for More Information
11:43 EDTGILDGilead says negotiations ongoing with major U.S. payors for Harvoni
Subscribe for More Information
11:10 EDTGILDGilead drops, levels to watch
Subscribe for More Information
10:59 EDTAAPLApple rises after Credit Suisse, Canaccord hike iPhone estimates
Shares of Apple (AAPL) are climbing after two research firms issued upbeat notes on the company in notes to investors today. WHAT'S NEW: Credit Suisse analyst Kulbinder Garcha upgraded Apple to Outperform from Market Perform. The company should sell 215M iPhones in both fiscal 2015 and fiscal 2016, Garcha estimated. Meanwhile, Apple's gross margins are being boosted by the increased popularity of both its 64 GB memory phones and of the IPhone 6 Plus, the analyst stated. Garcha increased his earnings per share estimate for the iPhone maker by 18% in fiscal 2015 and 20% in fiscal 2016. Additionally, the firm believes excessive net cash levels indicate a new $200B return program should occur. The analyst thinks the shares can reach $130 at least. After analyzing surveys in the U.S. that took place in December and into January, Canaccord analyst T. Michael Walkley said the surveys showed strong demand and market share gains for the new iPhones. The analyst increased his iPhone estimates for Apple's December quarter, as well as his estimates for the company's overall December quarter results. The increases were based on the positive demand trends, particularly for models with higher memory levels and prices, Walkley stated. He expects these positive trends to continue and reiterated a $135 price target and Buy rating on the shares. PRICE ACTION: In mid-morning trading, Apple climbed $3.39, or 3.1%, to $112.64.
10:00 EDTAAPLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:44 EDTMRKMerck makes $50M equity investment in Moderna under collaboration
Subscribe for More Information
09:36 EDTGILD, AAPLActive equity options trading
Active equity options trading according to Track Data: AAPL AMD AA TWTR GILD C CELG TSLA GOOG
09:07 EDTAAPLOn The Fly: Pre-market Movers
HIGHER: Apple (AAPL), up 1.4% after Credit Suisse upgraded Apple to Outperform and raised its iPhone volume estimates again... Best Buy (BBY), up 2.8% after being upgraded to Buy from Neutral at Goldman... SunPower (SPWR), up 2.6% after being upgraded to Outperform at Credit Suisse... Alcoa (AA), up 2% after Q4 results beat expectations. RISING AFTER GUIDANCE: Pharmacyclics (PCYC), up 17.5%... CTI BioPharma (CTIC), up 8.3%... Emulex (ELX), up 15.5%... ARIAD (ARIA), up 2.6%. LOWER: ChannelAdvisor (ECOM), down 42% following preliminary fourth quarter revenue guidance and after receiving multiple analyst downgrades... Antares Pharma (ATRS), down 7.7% after the FDA recommended that the company create a larger safety database for its clinical development program for QuickShot Testosterone.
08:08 EDTMRKEli Lilly, Merck enter collaborationa greement to evaluate Keytruda, compounds
Merck (MRK) and Eli Lilly and Company (LLY) announced an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials: Merck will conduct a Phase 2 study examining the combination of pembrolizumab with pemetrexed in first-line non-squamous, non-small cell lung cancer. This study is currently enrolling. Lilly will conduct a multiple-arm Phase 1/2 study examining the combination of ramucirumab with pembrolizumab in multiple tumors. This study is anticipated to begin in 2015. Lilly will conduct a Phase 1/2 study examining the combination of necitumumab with pembrolizumab in NSCLC. This study is anticipated to begin in 2015. The agreement is between Lilly and Merck, through a subsidiary. Additional details of the collaboration were not disclosed.
07:42 EDTGILDJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
07:36 EDTAAPLApple survey suggests demand remains strong, says Canaccord
Subscribe for More Information
07:18 EDTAAPLQuanta ramps up production of 12-inch MacBook Air, DigiTimes reports
Subscribe for More Information
06:56 EDTTSNTyson may see 'some impact' to business by China poultry ban, WSJ says
Subscribe for More Information
06:21 EDTAAPLApple upgraded at Credit Suisse
As previously reported, Credit Suisse upgraded Apple to Outperform from Neutral. The firm raised iPhone volume estimates again to 215M units for both FY15/16 and sees $10 EPS power in CY16 based on a solid and sustainable iPhone trends combined with a muted response from Samsung. Additionally, the firm believes excessive net cash levels indicate a new $200B return program should occur. Price target raised to $130 from $110.
06:20 EDTAAPLApple supplier shows 'unbreakable' smartphone with sapphire display, WSJ says
Subscribe for More Information
06:18 EDTAAPLSilicon Valley shuttle drivers looking to unionize, USA Today reports
Subscribe for More Information
06:10 EDTACHNAchillion implied volatility of 98 at lower end of index mean range
Subscribe for More Information
06:09 EDTAAPLApple implied volatility of 38 at upper end of index mean range
Subscribe for More Information
06:06 EDTAAPLApple upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use